T. Rowe Price Associates
ACHV icon

T. Rowe Price Associates’s Achieve Life Sciences ACHV Stock Holding History

T. Rowe Price Associates’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,474
Closed -$36K – 3059
2025
Q1 		$36K Hold
13,474
– – ﹤0.01% 2962
2024
Q4 		$48K Buy
13,474
+2,389
+22% +$10.8K ﹤0.01% 2948
2024
Q3 		$53K Hold
11,085
– – ﹤0.01% 2919
2024
Q2 		$0 Buy
+11,085
New +$53.4K ﹤0.01% 2922
2017
Q3 		– Sell
-21
Closed -$17K – 2570
2017
Q2 		$17K Hold
21
– – ﹤0.01% 2548
2017
Q1 		$20K Hold
21
– – ﹤0.01% 2562
2016
Q4 		$23K Hold
21
– – ﹤0.01% 2541
2016
Q3 		$23K Hold
21
– – ﹤0.01% 2517
2016
Q2 		$46K Hold
21
– – ﹤0.01% 2481
2016
Q1 		$32K Hold
21
– – ﹤0.01% 2484
2015
Q4 		$56K Hold
21
– – ﹤0.01% 2470
2015
Q3 		$103K Buy
21
+5
+31% +$30.1K ﹤0.01% 2405
2015
Q2 		$84K Buy
16
+1
+7% +$4.96K ﹤0.01% 2475
2015
Q1 		$70K Buy
15
+4
+36% +$19.6K ﹤0.01% 2499
2014
Q4 		$56K Buy
11
+3
+38% +$14.7K ﹤0.01% 2513
2014
Q3 		$47K Hold
8
– – ﹤0.01% 2522
2014
Q2 		$65K Buy
+8
New +$98.3K ﹤0.01% 2497

Other funds holding ACHV

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's ACHV Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Achieve Life Sciences (ACHV) in Q2 2025, closing a stake of 13,474 shares — an estimated $36K sold.

T. Rowe Price Associates first reported a position in ACHV in Q2 2014 and held it in 17 quarters. The position peaked at $103K in Q3 2015. 65 funds tracked by Wall St. Rank hold ACHV as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Achieve Life Sciences position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 13,474 Achieve Life Sciences shares in Q2 2025, an estimated $36K.
  • T. Rowe Price Associates first reported a position in Achieve Life Sciences in Q2 2014 and held it in 17 quarters.
  • T. Rowe Price Associates's Achieve Life Sciences position peaked at $103K in Q3 2015.
  • 65 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.